Conatus Pharma initiates P2 for its liver disease product

Conatus Pharmaceuticals (CNAT), a clinical stage biotech, announces that it has initiated a Phase 2 clinical trial for its lead product, emricasan, a novel treatment for patients with nonalcoholic fatty liver disease (NAFLD).

The study will enroll 40 patients at four US sites. The primary endpoint is a reduction of elevated levels of key biomarkers implicated in the disease.

The company expects top-line results in the second half of this year.

Conatus shares currently trade at $11, up 15% from its July 26 opening day close of $9.60.

74 mutual funds are owners.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs